retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Triple Agonism Based Therapies for
Description
Many individuals noted that the side effects wore off as their body adjusted to the drug, but initially they experienced nausea (24%), abdominal pain and headaches (both 23%) as well as diarrhea (20%)
Sci Transl Med (2013) 5(209):209ra151
10.1038/515182a [DOI] [PubMed] [Google Scholar] Lee Y
Because iron needs vary between individuals, supplementation decisions are often best made with guidance from a healthcare provider
Elsayed S
167 Careful use of GLP-1RA in MASLD patients, with or without a history of AP, may be beneficial, but more prospective studies are needed to confirm this
